Features of MCL with an indolent disease course
| Patient . | Age, y/sex . | CD markers by flow cytometry . | Diagnostic tissue . | Growth pattern lymphatic tissue . | Blastoid . | MIB1, % . | Growth pattern BM . | SOX11+ . | p53* . | MIPI . | Stage . | Splenomegaly . | > 4 Nodal sites . | Extra nodal . | Leukemic . | B symptoms . | ECOG score > 2 . | TTT, d . | ASCT . | Follow-up, d (status) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | 87.1/F | +20/5/23dim/L, −10 | GI | NA | 0 | 12 | Nodular | 0 | 0 | 3 | 4 | 0 | 0 | 1 | 0 | 0 | 0 | Not treated | 0 | 1090 (A) |
| 40 | 78.7/M | +20/5/23dim/L, −10 | LN | Nodular, MZ | 0 | 31 | Nodular | 1 | 0 | 3 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | Not treated | 0 | 2446 (A) |
| 57 | 76.0/M | +20/5/23dim/K, −10 | LN | Nodular | 0 | 55 | NA | 1 | 0 | 3 | 4 | 1 | 1 | 1 | 1 | 1 | 0 | 1889 | 0 | 2168 (D) |
| 63 | 79.8/M | +20/5/23/L, −10 | LN | In situ, MZ | 0 | ND | Nodular | 1 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 778 | 0 | 795 (A) |
| 66 | 69.8/M | +20/5/23dim/K, −10 | BM | NA | 0 | 16 | Nodular and diffuse | 1 | 0 | 2 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 786 | 0 | 1127 (D) |
| 68 | 76.9/M | +20/5/23dim/K, −10 | BM | NA | 0 | 4 | Interstitial, small groups | 1 | 0 | 2 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 1155 | 0 | 1542 (A) |
| 74 | 69.6/M | +20/5/23dim/L, −10 | LN | Nodular, MZ | 0 | 19 | Interstitial | 1 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | Not treated | 0 | 971 (D) |
| 77 | 70.7/F | +20/5/23dim/K, −10 | LN | Nodular, MZ | 0 | 15 | Interstitial | 1 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1100 | 0 | 1450 (D) |
| 84 | 75.5/F | +20/5/23dim/L, −10 | LN | MZ | 0 | 12 | Small aggregates | 1 | 0 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | Not treated | 0 | 900 (A) |
| 98 | 72.5/F | +20/5/K, −23/10 | GI, LN | Diffuse, MZ | 0 | 2 | Interstitial | 1 | 0 | 2 | 4 | 0 | 1 | 1 | 0 | 0 | 0 | Not treated | 0 | 1105 (A) |
| 100 | 69.7/M | +20/K, −5/23/10 | LN | MZ | 0 | 13 | NA | 1 | 0 | ND | 3 | ND | 1 | 0 | 0 | 0 | 0 | Not treated | 0 | 1589 (D) |
| 132 | 55.7/M | +20/5/L, −23/10, +23 in blood | Colon | Diffuse, MZ | 0 | 18 | NA | 1 | 0 | ND | 4 | 1 | 1 | 1 | 0 | 0 | ND | 2146 | 1 | 4783 (A) |
| 137 | 63.7/M | +20/5/23/L, −10 | LN | Diffuse, MZ | 0 | 29 | NA | 1 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | Not treated | 0 | 1252 (A) |
| 139 | 64.1/M | +20/5/K, −23/10 | BM | NA | 0 | ND | Interstitial, small groups | 0 | 1 | 3 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | Not treated | 0 | 1038 (A) |
| 151 | 61.2/M | +20/K, −5/23/10 | LN | Diffuse, MZ | 0 | 14 | NA | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | Not treated | 0 | 1173 (A) |
| 166 | 50.2/M | +20/5/K, − 23/10 | BM | NA | 0 | ND | Interstitial, small groups | 1 | 1 | 2 | 4 | 1 | 0 | ND | 1 | 0 | 0 | Not treated | 0 | 3488 (A) |
| 176 | 41.1/M | +20/5/23dim/L, −23/10 | Tonsil | Diffuse, MZ | 0 | 9 | NA | 1 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 1533 | 0 | 1783 (A) |
| Patient . | Age, y/sex . | CD markers by flow cytometry . | Diagnostic tissue . | Growth pattern lymphatic tissue . | Blastoid . | MIB1, % . | Growth pattern BM . | SOX11+ . | p53* . | MIPI . | Stage . | Splenomegaly . | > 4 Nodal sites . | Extra nodal . | Leukemic . | B symptoms . | ECOG score > 2 . | TTT, d . | ASCT . | Follow-up, d (status) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | 87.1/F | +20/5/23dim/L, −10 | GI | NA | 0 | 12 | Nodular | 0 | 0 | 3 | 4 | 0 | 0 | 1 | 0 | 0 | 0 | Not treated | 0 | 1090 (A) |
| 40 | 78.7/M | +20/5/23dim/L, −10 | LN | Nodular, MZ | 0 | 31 | Nodular | 1 | 0 | 3 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | Not treated | 0 | 2446 (A) |
| 57 | 76.0/M | +20/5/23dim/K, −10 | LN | Nodular | 0 | 55 | NA | 1 | 0 | 3 | 4 | 1 | 1 | 1 | 1 | 1 | 0 | 1889 | 0 | 2168 (D) |
| 63 | 79.8/M | +20/5/23/L, −10 | LN | In situ, MZ | 0 | ND | Nodular | 1 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 778 | 0 | 795 (A) |
| 66 | 69.8/M | +20/5/23dim/K, −10 | BM | NA | 0 | 16 | Nodular and diffuse | 1 | 0 | 2 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 786 | 0 | 1127 (D) |
| 68 | 76.9/M | +20/5/23dim/K, −10 | BM | NA | 0 | 4 | Interstitial, small groups | 1 | 0 | 2 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 1155 | 0 | 1542 (A) |
| 74 | 69.6/M | +20/5/23dim/L, −10 | LN | Nodular, MZ | 0 | 19 | Interstitial | 1 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | Not treated | 0 | 971 (D) |
| 77 | 70.7/F | +20/5/23dim/K, −10 | LN | Nodular, MZ | 0 | 15 | Interstitial | 1 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1100 | 0 | 1450 (D) |
| 84 | 75.5/F | +20/5/23dim/L, −10 | LN | MZ | 0 | 12 | Small aggregates | 1 | 0 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | Not treated | 0 | 900 (A) |
| 98 | 72.5/F | +20/5/K, −23/10 | GI, LN | Diffuse, MZ | 0 | 2 | Interstitial | 1 | 0 | 2 | 4 | 0 | 1 | 1 | 0 | 0 | 0 | Not treated | 0 | 1105 (A) |
| 100 | 69.7/M | +20/K, −5/23/10 | LN | MZ | 0 | 13 | NA | 1 | 0 | ND | 3 | ND | 1 | 0 | 0 | 0 | 0 | Not treated | 0 | 1589 (D) |
| 132 | 55.7/M | +20/5/L, −23/10, +23 in blood | Colon | Diffuse, MZ | 0 | 18 | NA | 1 | 0 | ND | 4 | 1 | 1 | 1 | 0 | 0 | ND | 2146 | 1 | 4783 (A) |
| 137 | 63.7/M | +20/5/23/L, −10 | LN | Diffuse, MZ | 0 | 29 | NA | 1 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | Not treated | 0 | 1252 (A) |
| 139 | 64.1/M | +20/5/K, −23/10 | BM | NA | 0 | ND | Interstitial, small groups | 0 | 1 | 3 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | Not treated | 0 | 1038 (A) |
| 151 | 61.2/M | +20/K, −5/23/10 | LN | Diffuse, MZ | 0 | 14 | NA | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | Not treated | 0 | 1173 (A) |
| 166 | 50.2/M | +20/5/K, − 23/10 | BM | NA | 0 | ND | Interstitial, small groups | 1 | 1 | 2 | 4 | 1 | 0 | ND | 1 | 0 | 0 | Not treated | 0 | 3488 (A) |
| 176 | 41.1/M | +20/5/23dim/L, −23/10 | Tonsil | Diffuse, MZ | 0 | 9 | NA | 1 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 1533 | 0 | 1783 (A) |
MIB1 indicates proliferation as measured by Ki-67 staining; BM, bone marrow; MIPI, MCL International Prognostic Index; ECOG, Eastern Cooperative Oncology Group; TTT, time to treatment; ASCT, autologous stem cell transplantation; GI, gastrointestinal; NA, not applicable; 0, negative; 1, positive; A, alive; LN, lymph node; MZ, mantle zone growth pattern; D, dead; and ND, not done.
p53 positivity in > 20% of the tumor cells by immunohistochemistry.